Yahoo
ASX - Delayed Quote AUD

Genetic Signatures Limited (GSS.AX)

0.0780 -0.0010 (-1.27%)
At close: October 30 at 3:46:22 PM GMT+11
Chart Range Bar
Loading chart for GSS.AX
  • Previous Close 0.0790
  • Open 0.0770
  • Bid 0.0750 x --
  • Ask 0.0790 x --
  • Day's Range 0.0760 - 0.0790
  • 52 Week Range 0.0510 - 0.3450
  • Volume 184,344
  • Avg. Volume 478,043
  • Market Cap (intraday) 17.717M
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 0.31

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.

www.geneticsignatures.com

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

GSS.AX
68.80%
S&P/ASX 200 [XJO] (^AXJO)
2.22%

1-Year Return

GSS.AX
74.43%
S&P/ASX 200 [XJO] (^AXJO)
0.29%

3-Year Return

GSS.AX
84.03%
S&P/ASX 200 [XJO] (^AXJO)
31.37%

5-Year Return

GSS.AX
94.25%
S&P/ASX 200 [XJO] (^AXJO)
21.63%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 3.3M
Earnings --
Profit Margin 0.00%

Q4

FY20

Q2

FY26

0
1M
2M
3M
4M
5M
0.0%

Analyst Insights

View More

Analyst Price Targets

0.31
0.31 Average
0.0780 Current
0.31 High

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -72.45%

  • Return on Assets (ttm)

    -17.27%

  • Return on Equity (ttm)

    -32.64%

  • Revenue (ttm)

    19.33M

  • Net Income Avi to Common (ttm)

    -14.01M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    22.09M

  • Total Debt/Equity (mrq)

    0.87%

  • Levered Free Cash Flow (ttm)

    -5.1M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: